Cancer Immunology Training Program
Cancer Immunology Training Program
批准号:
10670409
负责人:
Robert J Binder
金额:
$51.87万
依托单位国家:
美国
项目类别:
财政年份:
1999
资助国家:
美国
项目状态:
未结题
起止时间:
1999-07-01 至 2027-06-30
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
Interest in cancer immunology has never been more intense. Breakthrough observations with inhibitory receptor
blockade, combined with ground breaking advances in the use of chimeric antigen receptor (CAR)-modified T
cell adoptive therapies have highlighted the critical need to further basic and translation research in cancer
immunology. While the pipeline of potential immunotherapeutic targets is growing, the pipeline of future cancer
immunologists is limited, in part due to significant demand in industry and academia. There is a critical need for
training programs that optimally prepare the next generation of cancer immunologists. Surprisingly, our Cancer
Immunology Training Program (CITP) at the University of Pittsburgh School of Medicine (UPSOM) is one of only
six NCI-supported T32s nationwide that focus entirely on cancer immunology. This makes our program
unique and essential. CITP, which has 5 pre- and 3 post-doctoral slots, is in its 20th year and we are seeking
support for the next five years. The goals of the CITP are to provide graduate students, fellows and physician
scientists with courses, research projects, exceptional environment and resources, and highly-qualified mentors
that will allow them to: (1) make a significant contribution to one of five areas of research focus covered by this
training program: (a) Inhibitory Mechanisms in the Tumor Microenvironment (TME), (b) Adaptive Immunity and
Cellular Interactions within the TME, (c) Innate, Environmental and Metabolic Modulation, (d) Promoting Immune
Responses to Tumors: Cell-Based Therapies & Vaccines, and (e) Systems Cancer Immunology; (2) gain a clear
understanding of the cellular and molecular mechanisms relevant to cancer immunology; (3) obtain a practical
understanding of the immunology of human cancer; (4) gain a clear conceptual understanding of all areas that
impact cancer immunology; and (5) develop critical career skills and managerial ability. Building thoughtfully on
what is a proven training program, we have made several enhancements, such as increasing the cancer
immunology-focus of our faculty (25 total). UPSOM and HCC have and continue to make an unprecedented
investment in cancer immunology. The training program exploits particular strengths at UPSOM, including an
exceptional NCI Comprehensive Cancer Center, a strong immuno-centric translational research base, an
outstanding Immunology Department that underpins strong basic research, and our graduate research program
(PMI). UPSOM has implemented effective programs to ensure outstanding training, with emphasis on increasing
the recruitment and retention of women and URMs. Our applicant pool is exceptional due to the success of our
PMI and MSTP graduate programs, highly sought-after clinical fellowships, and outstanding mentor pool. Over
the last 5 years, CITP has enrolled 24 trainees (Pre – 15; Post – 9), of which 13 were women (54%) and 3 were
URM (12.5%). Lastly, our trainees have been extremely successful in obtaining extramural/competitive
fellowships (14 total [58%]: F99/K00 [1], F32 [3], F31 [4], F30 [3], Damon-Runyon [1], St. Baldrick's [1],
Hartwell [1]). We are excited and eager to train the next generation of cancer immunologists.
期刊论文(71)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1002/eji.200939667
发表时间:
2010-02
期刊:
EUROPEAN JOURNAL OF IMMUNOLOGY
影响因子:
5.4
作者:
[Lipscomb, Michael W., Taylor, Jennifer L., Goldbach, Cristina J., Watkins, Simon C., Wesa, Amy K., Storkus, Walter J.]
通讯作者:
Storkus, Walter J.
Immune-checkpoint blockade and active immunotherapy for glioma.
免疫检查点阻滞和神经胶质瘤的主动免疫疗法。
DOI:
10.3390/cancers5041379
发表时间:
2013-11-01
期刊:
Cancers
影响因子:
5.2
作者:
[Ahn BJ, Pollack IF, Okada H]
通讯作者:
Okada H
DOI:
10.1158/0008-5472.can-10-1369
发表时间:
2010-11-15
期刊:
Cancer research
影响因子:
11.2
作者:
[Pardee AD, McCurry D, Alber S, Hu P, Epstein AL, Storkus WJ]
通讯作者:
Storkus WJ
DOI:
10.4049/jimmunol.1401608
发表时间:
2014-11-01
期刊:
Journal of immunology (Baltimore, Md. : 1950)
影响因子:
--
作者:
[Park KS, Bayles I, Szlachta-McGinn A, Paul J, Boiko J, Santos P, Liu J, Wang Z, Borghesi L, Milcarek C]
通讯作者:
Milcarek C
Molecular recognition patterns of serum anti-DNA topoisomerase I antibody in systemic sclerosis.
系统性硬化症血清抗 DNA 拓扑异构酶 I 抗体的分子识别模式。
DOI:
10.4049/jimmunol.173.4.2834
发表时间:
2004
期刊:
Journal of immunology (Baltimore, Md. : 1950)
影响因子:
--
作者:
[Hu,PaulQ, Fertig,Noreen, MedsgerJr,ThomasA, Wright,TimothyM]
通讯作者:
Wright,TimothyM
共 40 条
CD91 and cancer immunosurveillance
-
批准号:10308038
-
项目类别:
-
资助金额:$34.78万
-
财政年份:2019
-
负责人:Robert J Binder
-
依托单位:
CD91 and cancer immunosurveillance
-
批准号:9897031
-
项目类别:
-
资助金额:$35.49万
-
财政年份:2019
-
负责人:Robert J Binder
-
依托单位:
CD91 and cancer immunosurveillance
-
批准号:10524051
-
项目类别:
-
资助金额:$34.78万
-
财政年份:2019
-
负责人:Robert J Binder
-
依托单位:
Heat shock protein gp96 and Treg responses
-
批准号:9606843
-
项目类别:
-
资助金额:$19.43万
-
财政年份:2018
-
负责人:Robert J Binder
-
依托单位:
Heat shock proteins and modulation of immune responses
-
批准号:9307761
-
项目类别:
-
资助金额:$16.81万
-
财政年份:2016
-
负责人:Robert J Binder
-
依托单位:
Role of CD91 and its ligands in immune response
-
批准号:8094481
-
项目类别:
-
资助金额:$32.85万
-
财政年份:2009
-
负责人:Robert J Binder
-
依托单位:
Role of CD91 and its ligands in immune response
-
批准号:8488395
-
项目类别:
-
资助金额:$30.88万
-
财政年份:2009
-
负责人:Robert J Binder
-
依托单位:
Role for alpha2-Macroglobulin in Immune Responses and Cancer Immunotherapy
-
批准号:7573852
-
项目类别:
-
资助金额:$15.19万
-
财政年份:2009
-
负责人:Robert J Binder
-
依托单位:
Role of CD91 and its ligands in immune response
-
批准号:8290437
-
项目类别:
-
资助金额:$32.85万
-
财政年份:2009
-
负责人:Robert J Binder
-
依托单位:
Role of CD91 and its ligands in immune response
-
批准号:7727754
-
项目类别:
-
资助金额:$33.15万
-
财政年份:2009
-
负责人:Robert J Binder
-
依托单位:
Role of CD91 and its ligands in immune response
-
批准号:7877729
-
项目类别:
-
资助金额:$33.18万
-
财政年份:2009
-
负责人:Robert J Binder
-
依托单位:
Role for alpha2-Macroglobulin in Immune Responses and Cancer Immunotherapy
-
批准号:8103864
-
项目类别:
-
资助金额:$16.0万
-
财政年份:2009
-
负责人:Robert J Binder
-
依托单位:
Role for alpha2-Macroglobulin in Immune Responses and Cancer Immunotherapy
-
批准号:7886878
-
项目类别:
-
资助金额:$15.59万
-
财政年份:2009
-
负责人:Robert J Binder
-
依托单位:
Cancer Immunology Training Program
-
批准号:10492141
-
项目类别:
-
资助金额:$34.73万
-
财政年份:1999
-
负责人:Robert J Binder
-
依托单位:
海外基金